Sunday, March 19, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

BARDA Chem and RadNuc Animal Model Development

by Global Biodefense Staff
December 10, 2014
Technology Review Shows Past and Future of Biodetection

Credit: Shutterstock

The Biomedical Advanced Research and Development Authority (BARDA) has issued a notice seeking laboratory research services to establish new or existing animal models for the development of Chemical and Radiological/Nuclear Medical Countermeasures (MCMs).

BARDA anticipates that contracts awarded from effort will serve to facilitate the animal model development of medical countermeasures and supportive reagents and assays for regulatory acceptance in the U.S.

In these models, the challenge dose generally should be the same as that which produces the human disease or condition and the pathophysiological mechanism of its toxicity should be reasonably well-understood and mimic the human condition as closely as possible.

When these models are used to test the efficacy of potential MCMs for threat agents, the mechanism of action of the countermeasure will need to establish the utility of the animal model as a surrogate for humans.

It is anticipated that the official RFP will be released January 20, 2015, with proposals being due on or about March 4, 2015. Multiple awards may result from this solicitation with an estimated award date in July 2015.

Further details are available under Solicitation Number: RFP-15-100-SOL-00004.

Editor’s Note: The release date for the RFP was postponed until on/about Mar 17, 2015.

Tags: Animal ModelsASPRBARDAChemical DetectionHHSRadiation

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC